PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices for the interventional therapy market. Headquartered in Alameda, California, the company was founded in 2004 and operates through two primary segments: vascular and neuro. Penumbra's product portfolio includes aspiration-based thrombectomy systems, embolization coils, access devices, and computer-assisted vacuum thrombectomy systems used to treat conditions such as acute ischemic stroke, pulmonary embolism, and peripheral vascular disease. The company's flagship products include the Penumbra System for neurovascular applications and the Indigo System for venous thromboembolism treatment. Penumbra markets its products globally, with significant operations in the United States, Europe, and Asia-Pacific regions, serving hospitals and healthcare providers through a direct sales force and distribution partners. The company employs approximately 3,700 people worldwide and maintains research, development, and manufacturing facilities in the United States and internationally. Recent strategic initiatives include expanding its thrombectomy portfolio, advancing its immersive healthcare platform through subsidiary Penumbra Physicians Organization, and pursuing regulatory approvals for new device applications. Penumbra competes in the rapidly growing interventional medical device market, focusing on mechanical thrombectomy and vascular access technologies that address time-sensitive conditions requiring minimally invasive treatment approaches.